CN102698250A - Injection for alcoholic liver and fatty liver - Google Patents
Injection for alcoholic liver and fatty liver Download PDFInfo
- Publication number
- CN102698250A CN102698250A CN201210189928XA CN201210189928A CN102698250A CN 102698250 A CN102698250 A CN 102698250A CN 201210189928X A CN201210189928X A CN 201210189928XA CN 201210189928 A CN201210189928 A CN 201210189928A CN 102698250 A CN102698250 A CN 102698250A
- Authority
- CN
- China
- Prior art keywords
- liver
- injection
- vit
- alcoholic
- fatty liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of medicines, in particular to injection for alcoholic liver and fatty liver. The injection in each dosage comprises glutathione, tauric acid, 400 to 600mg of MgSO4, Minophagen-C, vitamin B complex, Vit B6, Vit B12 and Vit C in a certain ratio. The glutathione in the formula can protect liver cell membranes and scavenge free radicals; tauric acid is matched with the Minophagen-C and the MgSO4 to clear fat in liver and restore liver functions; and the injection can clear the fat in the liver and restore the liver functions in a short time, and has the advantages of short treatment course, quick response and no toxic or side effect compared with the conventional treatment scheme.
Description
Technical field
The present invention relates to medical technical field, refer in particular to the injection of a kind of alcoholic liver, fatty liver.
Background technology
Hepatic disease is the commonly encountered diseases and the frequently-occurring disease of China; Common have alcoholic liver, fatty liver, alcoholic liver, an alcoholic liver disease; Initial stage shows as fatty liver usually; And then develop into alcoholic hepatitis, alcoholic fibrosis and alcoholic cirrhosis, when seriously indulging in excessive drinking, even can bring out extensive hepatic necrosis liver failure.Alcoholic liver is to occur the most common pathological changes in the alcoholic liver disease the earliest.Alcoholic liver is because the hepar damnification property disease due to the long-term heavy drinking (being addicted to drink), and alcoholic liver patient is not as taking effective measures, and the state of an illness will continue to worsen and increase the weight of, and can occur alcoholic hepatitis, hepatic fibrosis and generation liver cirrhosis gradually.
With the quickening pace of modern life, the raising of quality of life, increasing people becomes the patient of fatty liver.Long-term a large amount of drinking, the food of taking in high heat is too much, and the influence of some hepatitis and diabetes all might cause fatty liver.Fatty liver is meant because the pathological changes of fatty overheap in the hepatocyte that causes of a variety of causes.The positive serious threat compatriots' of fatty liver disease health becomes the second largest hepatopathy that is only second to viral hepatitis, has been acknowledged as the common cause of disguised liver cirrhosis.Fatty liver is a kind of common clinical picture, but not a kind of independently disease.The lighter is asymptomatic in its clinical manifestation, and weight person's state of an illness is violent.Generally speaking, fatty liver belongs to the reversibility disease, and early diagnosis and treatment in time often can recover normal.
Therefore hepatopathy is a process that long-term accumulation is hidden; Alcoholic liver, fatty liver to early stage need cause enough attention; At present hepatopathy generally be after morbidity the later stage just draw attention, not having preferably to alcoholic liver, the fatty liver in hepatic disease early stage, medicine carries out efficacious therapy.Treat and also have at present be directed against, general recommendations is moved nothing more than, diet and medicine, and common drug is long the course of treatment, and effect is indeterminate, takes medicine for a long time and also can damage liver function.
Summary of the invention
The alcoholic liver, the fatty liver that the present invention is directed to present early stage do not have the deficiency that active drug is treated, and the injection of a kind of alcoholic liver, fatty liver is provided, and for realizing above purpose, the present invention adopts following technical scheme:
The injection of a kind of alcoholic liver, fatty liver, described injection comprise effective healing potion and pharmaceutically acceptable pharmaceutic adjuvant, and the every dosage of said injection contains said healing potion and is: glutathion 1.8-3.6g, taurine 10-30mg, MgSO
4400-600mg, Minophagen-C (potenxin) 40-80mg, compound vitamin B 2-6cc, Vit B610-30mg, Vit B12 500-1000ug, Vit C 3g-10g.
Preferable, the every dosage of said injection contains said healing potion and is: glutathion 2g, taurine 15mg, MgSO
4500mg, Minophagen-C (potenxin) 65mg, compound vitamin B 4cc, Vit B6 20mg, Vit B12600ug, Vit C7g.
Preferable, said pharmaceutic adjuvant is one or more combination of fructose, lactose, ribose, arabinose, glucose, mannitol, xylitol, sorbitol, low molecular dextran, calcium gluconate, calcium phosphate, aminoacid, sodium chloride.
Beneficial effect of the present invention is: the injection of alcoholic liver of the present invention, fatty liver, every dosage injection comprises a certain amount of glutathion, cattle sulphur, MgSO
4400-600mg, Minophagen-C (potenxin), compound vitamin B, Vit B6, Vit B12, Vit C, the glutathion in the prescription can be protected liver plasma membrane, removes free radical; Taurine cooperates potenxin, magnesium sulfate can know intrahepatic fat, recovering liver function; Injection of the present invention can be removed intrahepatic fat in a short time, repairs liver function, compares with existing therapeutic scheme, short treating period is arranged, instant effect, advantage without any side effects.
The specific embodiment:
Below in conjunction with specific embodiment the present invention is further specified:
Embodiment 1:
The healing potion that the every dosage of the injection of present embodiment contains is: glutathion 1.8g, taurine 30mg, MgSO
4400mg, Minophagen-C (potenxin) 80mg, compound vitamin B 2cc, Vit B6 30mg, Vit B12 500ug, Vit C 10g, pharmaceutic adjuvant of the present invention is selected fructose; Adopt medical distilled water to be configured to the high capacity injection of 50ml; Pharmaceutical knowledge well-known to those skilled in the art; Pharmaceutic adjuvant is except the used fructose of present embodiment; Also can be selected from one or more combination of lactose, ribose, arabinose, glucose, mannitol, xylitol, sorbitol, low molecular dextran, calcium gluconate, calcium phosphate, aminoacid, sodium chloride, for the weight of the pharmaceutic adjuvant that adds, these those skilled in the art can do rational interpolation; For institute's preparation agents choice of capacity, also can do the dosage of the form of different capabilities according to demand.
Embodiment 2:
The healing potion that the every dosage of the injection of present embodiment contains is: ginkgo bilobate extract: glutathion 3.6g, taurine 10mg, MgSO
4600mg, Minophagen-C (potenxin) 40mg, compound vitamin b6 cc, Vit B6 10mg, Vit B12 1000ug, Vit C 3g, the pharmaceutic adjuvant of present embodiment is selected aminoacid, sodium chloride for use.
Embodiment 3:
The healing potion that the every dosage of the injection of present embodiment contains is: glutathion 2g, taurine 15mg, MgSO
4500mg, Minophagen-C (potenxin) 65mg, compound vitamin B 4cc, Vit B6 20mg, Vit B12600ug, Vit C7g.The pharmaceutic adjuvant of present embodiment is selected calcium gluconate, calcium phosphate for use.
The dosage of injection of the present invention is filled a prescription with normal adult dosage; The doctor according to patient's body constitution and age can be suitable the deal that increases and decreases this injection carry out medication; Product of the present invention is all obtained good efficacy in various degree through a lot of clinical verifications.Enumerate a case wherein at present: Zhang, the man, 38 years old, drink for a long time, it is rich to have a liking for food, easy fatigue.Make a definite diagnosis behind the B ultrasonic: moderate fatty liver, abnormal liver function, glutamate pyruvate transaminase 56U/L, glutamic oxaloacetic transaminase, GOT 78U/L; Adopt injection of the present invention to cooperate 250 ml physiological salines, 2 intravenous drips weekly, continuous 10 treatments, the check liver function, glutamate pyruvate transaminase 22U/L, glutamic oxaloacetic transaminase, GOT 35U/L, liver function recovery is normal, and fatigue alleviates, and nothing else is uncomfortable.
The above embodiment; It is preferred embodiments of the present invention; Be not to limit practical range of the present invention,, all should be included in the patent claim of the present invention so all equivalences of doing according to the described structure of claim of the present invention, characteristic and principle change or modify.
Claims (3)
1. the injection of an alcoholic liver, fatty liver; It is characterized in that: described injection comprises effective healing potion and pharmaceutically acceptable pharmaceutic adjuvant; The every dosage of said injection contains said healing potion: glutathion 1.8-3.6g, taurine 10-30mg, MgSO4 400-600mg, Minophagen-C (potenxin) 40-80mg, compound vitamin B 2-6cc, Vit B6 10-30mg, Vit B12 500-1000ug, Vit C 3g-10g.
2. the injection of a kind of alcoholic liver according to claim 1, fatty liver is characterized in that, the every dosage of said injection contains said healing potion and is: glutathion 2g, taurine 15mg, MgSO
4500mg, Minophagen-C (potenxin) 65mg, compound vitamin B 4cc, Vit B6 20mg, Vit B12600ug, Vit C7g.
3. the injection of a kind of alcoholic liver according to claim 1 and 2, fatty liver; It is characterized in that said pharmaceutic adjuvant is one or more combination of fructose, lactose, ribose, arabinose, glucose, mannitol, xylitol, sorbitol, low molecular dextran, calcium gluconate, calcium phosphate, aminoacid, sodium chloride
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210189928XA CN102698250A (en) | 2012-06-09 | 2012-06-09 | Injection for alcoholic liver and fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210189928XA CN102698250A (en) | 2012-06-09 | 2012-06-09 | Injection for alcoholic liver and fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102698250A true CN102698250A (en) | 2012-10-03 |
Family
ID=46891497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210189928XA Pending CN102698250A (en) | 2012-06-09 | 2012-06-09 | Injection for alcoholic liver and fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102698250A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726471A (en) * | 2016-03-16 | 2016-07-06 | 邓学峰 | Medicine composition with vitamin C and method for preparing medicine composition |
| CN106728405A (en) * | 2016-11-15 | 2017-05-31 | 陈思文 | A kind of taurine and water soluble tea polyphenol compound and preparation method and application |
| CN112089717A (en) * | 2020-08-25 | 2020-12-18 | 唐传生物科技（厦门）有限公司 | Application of arabinose and composition for preparing intestinal tract |
-
2012
- 2012-06-09 CN CN201210189928XA patent/CN102698250A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 吕瑞娟等: "脂肪肝的发病机理和治疗研究进展", 《甘肃科学学报》 * |
| 吴剑华: "常用的保肝药物及特点", 《中国社区医师》 * |
| 徐捷等: "硫酸镁的内科临床应用", 《现代中西医结合杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726471A (en) * | 2016-03-16 | 2016-07-06 | 邓学峰 | Medicine composition with vitamin C and method for preparing medicine composition |
| CN106728405A (en) * | 2016-11-15 | 2017-05-31 | 陈思文 | A kind of taurine and water soluble tea polyphenol compound and preparation method and application |
| CN112089717A (en) * | 2020-08-25 | 2020-12-18 | 唐传生物科技（厦门）有限公司 | Application of arabinose and composition for preparing intestinal tract |
| CN112089717B (en) * | 2020-08-25 | 2022-02-22 | 唐传生物科技（厦门）有限公司 | Application of arabinose and composition for preparing intestinal tract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chan et al. | The effect of stevioside on blood pressure and plasma catecholamines in spontaneously hypertensive rats | |
| US8952040B2 (en) | Pharmaceutical composition for treating coagulation disorder hemorrhage and method using the same | |
| TW200838545A (en) | Therapeutic agent for painful disease | |
| WO2012000377A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
| WO2016173486A1 (en) | Use of trimethazine in preparation of drugs for preventing and treating liver diseases | |
| JP2018523683A5 (en) | ||
| CN102698250A (en) | Injection for alcoholic liver and fatty liver | |
| JP5555401B2 (en) | Hepatitis C virus-positive human liver cirrhosis patient liver cancer occurrence / proliferation inhibitor | |
| CN103211141A (en) | Application of anti-hypoxia and anti-fatigue oral composition in health product | |
| US20220008455A1 (en) | Compound and Composition for Use in the Preventive and/or Curative Treatment of Diseases of the Central Nervous System Characterised by a Decline in Neuronal Plasticity, in Particular Characterised by a Decline in Synaptic Plasticity | |
| RU2015119377A (en) | DRUG FORMS FOR QUICK COUPLING OF PARKINSON'S DISEASE | |
| WO2012118172A1 (en) | Drug for improving central functions during pain | |
| JP2012214485A (en) | Inhibitor for onset and progress of liver cancer | |
| AU2010305384B2 (en) | Sulfonamides for the prevention of diabetes | |
| JP6250196B2 (en) | Diabetes treatment composition | |
| Henning et al. | Serum quinidine levels after administration of three different quinidine preparations | |
| Imai et al. | Do the effects of long-term lomerizine administration differ with age? | |
| FI3661518T3 (en) | Methods of treating symptoms of gastroparesis using velusetrag | |
| CN117503763A (en) | Application of palmatine in treating hypertension | |
| RU2481124C1 (en) | Pharmaceutical combination of atorvastatin and nicergolin for preventing or treating cerebrovascular disease | |
| RU2177320C1 (en) | Agent relieving expression of postintoxication alcoholic syndrome | |
| RU2008152700A (en) | USE OF LITHIUM SALTS FOR TREATMENT OF ACUTE RENAL FAILURE | |
| CN104434920B (en) | A kind of pharmaceutical composition treating heart failure and application thereof | |
| Lyles | Deep venous thrombophlebitis associated with lithium toxicity | |
| Vijayakumar | Chlorpromazine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121003 |